We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Avacta | LSE:AVCT | London | Ordinary Share | GB00BYYW9G87 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.25 | -0.58% | 43.00 | 42.00 | 44.00 | 44.00 | 42.50 | 43.25 | 797,907 | 16:16:18 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 23.25M | -24.95M | -0.0695 | -6.19 | 155.29M |
Date | Subject | Author | Discuss |
---|---|---|---|
03/10/2024 13:45 | Shorters closing ? | fieldhouse | |
03/10/2024 13:26 | Picking up now | robers98 | |
03/10/2024 13:21 | 60p then 70. TOO CHEAP HERE | gkace | |
03/10/2024 10:54 | Hahaha go and drain yourself you sap ;) | g2theary | |
03/10/2024 10:27 | Get in VAST then same there but there's a better chance of a substantial rise ;) I've picked a few here technical bounce but this moves when it gets going ;) | g2theary | |
03/10/2024 09:27 | back to 60p | gkace | |
03/10/2024 06:36 | I've followed this company for years and nothing I repeat nothing has ever come fruitful with promises and waffle, and it begs the question will it ever me personally I doubt it, ok for a daily trade, shame they really have had some good stories over the years lol, this time next year rodders, the ramps are getting tiresome like stuck record if you know what one is, the Nas listing's especially lol how many times we hear that old chestnut, oh and the being bought out, oh lord | repins1 | |
03/10/2024 06:13 | I don't post to make pp eeps ' throw in the towel' but to save them from financial ruin. Seen so many spout, crumble and disappear, 9/10 with small Aim cos. Aim chief execs looks after themselves ultimately, are on the Grift.The reg framework is weak - need X4 yearly accounting reports.It.s corrupt.GL Cheshire. | amanitaangelicus | |
03/10/2024 06:09 | I don't post to make pp eeps ' throw in the towel' but to save them from financial ruin. Seen so many spout, crumble and disappear, 9/10 with small Aim cos. Aim chief execs looks after themselves ultimately, are on the Grift.The reg framework is weak - need X4 yearly accounting reports.It.s corrupt.GL Cheshire. | amanitaangelicus | |
02/10/2024 19:31 | Yeah yeah, keep trying guys you'll get a few to throw in the towel and sell up. Not me though, here till take out whenever. | cheshire pete | |
02/10/2024 16:51 | The fact this is still such a long way from FDA approval with all the risks that involves and time it will take etc mean more fund raises are inevitable . Sadly like so many others that will be to shareholders detriment . Ava6000 might well be a great development but until it's a lot closer to approval I don't see any reason to buy here and the market cap looks very high given the risks and funding issues that will come down the line . I've looked several times and simply don't get the optimism at this stage having seen so many other biotechs get hammered due to funding | bones698 | |
02/10/2024 12:59 | Turner Pope note out | robers98 | |
02/10/2024 12:44 | Found some support though. Good. | amanitaangelicus | |
02/10/2024 12:16 | Considering how long the Phase 1a trial has been running that could be a long running series, you'd need lots of coffee to get through it. | 1347 | |
02/10/2024 09:44 | fieldhouse - Avacta can only make money from AVA6000 one way and that's if it turns the whole sorrowful story into a Netflix series. | pwhite73 | |
02/10/2024 09:30 | Myles pump is slowly dying | bladderman | |
02/10/2024 08:04 | Going forward , my guess is to licence a modified Ava6000 for use with dox.Hopefully funding phase 2 . The platform will be evaluated by the scientific team of eminent cardiologists. Numerous drugs will be evaluated on behalf of BP with additional licence fees . In the meantime,to overcome the undoubted cash requirement,the DX division will be sold. What we don’t know is how interested big pharma is and what value they put on the Ava at research . Unknown,unknowns I am afraid. overcome the undoubted cash hurdle ,the sale of the DX division. | fieldhouse | |
02/10/2024 07:50 | Aman is a yellow-bellied two faced coward who jumps from one position to another like a flea with hindsight. | pwhite73 | |
02/10/2024 07:40 | I think Aman has been vindicated with his views | fieldhouse | |
02/10/2024 07:37 | Owatfun, Have you not listened to the interviews and results presentation ? Cash runway is the problem and 2027 as a possible date for big data release from phase 2 | fieldhouse | |
02/10/2024 07:14 | Not the selling off etc ... | amanitaangelicus |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions